These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39123440)

  • 1. H-1 Parvovirus-Induced Oncolysis and Tumor Microenvironment Immune Modulation in a Novel Heterotypic Spheroid Model of Cutaneous T-Cell Lymphoma.
    Angelova A; Barf M; Just A; Leuchs B; Rommelaere J; Ungerechts G
    Cancers (Basel); 2024 Jul; 16(15):. PubMed ID: 39123440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.
    Angelova AL; Witzens-Harig M; Galabov AS; Rommelaere J
    Front Oncol; 2017; 7():93. PubMed ID: 28553616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.
    Angelova AL; Grekova SP; Heller A; Kuhlmann O; Soyka E; Giese T; Aprahamian M; Bour G; Rüffer S; Cziepluch C; Daeffler L; Rommelaere J; Werner J; Raykov Z; Giese NA
    J Virol; 2014 May; 88(10):5263-76. PubMed ID: 24574398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.
    Angelova AL; Aprahamian M; Balboni G; Delecluse HJ; Feederle R; Kiprianova I; Grekova SP; Galabov AS; Witzens-Harig M; Ho AD; Rommelaere J; Raykov Z
    Mol Ther; 2009 Jul; 17(7):1164-72. PubMed ID: 19367260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
    Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
    Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.
    Geletneky K; Kiprianova I; Ayache A; Koch R; Herrero Y Calle M; Deleu L; Sommer C; Thomas N; Rommelaere J; Schlehofer JR
    Neuro Oncol; 2010 Aug; 12(8):804-14. PubMed ID: 20299703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
    Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
    Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Testing of an Oncolytic Parvovirus: Standard Protoparvovirus H-1PV Efficiently Induces Osteosarcoma Cell Lysis In Vitro.
    Geiss C; Kis Z; Leuchs B; Frank-Stöhr M; Schlehofer JR; Rommelaere J; Dinsart C; Lacroix J
    Viruses; 2017 Oct; 9(10):. PubMed ID: 29039746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
    Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
    Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Complex Role of Infectious Agents in Human Cutaneous T-Cell Lymphoma Pathogenesis: From Candidate Etiological Factors to Potential Therapeutics.
    Angelova A; Rommelaere J; Ungerechts G
    Pathogens; 2024 Feb; 13(3):. PubMed ID: 38535528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry.
    Kulkarni A; Ferreira T; Bretscher C; Grewenig A; El-Andaloussi N; Bonifati S; Marttila T; Palissot V; Hossain JA; Azuaje F; Miletic H; Ystaas LAR; Golebiewska A; Niclou SP; Roeth R; Niesler B; Weiss A; Brino L; Marchini A
    Nat Commun; 2021 Jun; 12(1):3834. PubMed ID: 34158478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent.
    Grekova S; Aprahamian M; Giese N; Schmitt S; Giese T; Falk CS; Daeffler L; Cziepluch C; Rommelaere J; Raykov Z
    Cancer Biol Ther; 2010 Dec; 10(12):1280-9. PubMed ID: 21124075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.
    Moehler M; Sieben M; Roth S; Springsguth F; Leuchs B; Zeidler M; Dinsart C; Rommelaere J; Galle PR
    BMC Cancer; 2011 Oct; 11():464. PubMed ID: 22029859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells.
    Lacroix J; Leuchs B; Li J; Hristov G; Deubzer HE; Kulozik AE; Rommelaere J; Schlehofer JR; Witt O
    Int J Cancer; 2010 Sep; 127(5):1230-9. PubMed ID: 20087864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.
    Grekova SP; Aprahamian M; Daeffler L; Leuchs B; Angelova A; Giese T; Galabov A; Heller A; Giese NA; Rommelaere J; Raykov Z
    Cancer Biol Ther; 2011 Nov; 12(10):888-95. PubMed ID: 22024742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis.
    Ferreira T; Kulkarni A; Bretscher C; Richter K; Ehrlich M; Marchini A
    Viruses; 2020 Oct; 12(10):. PubMed ID: 33096814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells.
    Bhat R; Rommelaere J
    BMC Cancer; 2013 Jul; 13():367. PubMed ID: 23902851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
    Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
    Front Immunol; 2019; 10():1848. PubMed ID: 31440242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
    Bretscher C; Marchini A
    Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.
    Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
    J Biomed Biotechnol; 2010; 2010():350748. PubMed ID: 20224643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.